198 related articles for article (PubMed ID: 14675262)
1. Evolution of wild type and mutants of the YMDD motif of hepatitis B virus polymerase during lamivudine therapy.
Zhang X; Liu C; Gong Q; Zhang S; Zhang D; Lu Z; Wang Y
J Gastroenterol Hepatol; 2003 Dec; 18(12):1353-7. PubMed ID: 14675262
[TBL] [Abstract][Full Text] [Related]
2. Emergence and takeover of YMDD motif mutant hepatitis B virus during long-term lamivudine therapy and re-takeover by wild type after cessation of therapy.
Chayama K; Suzuki Y; Kobayashi M; Kobayashi M; Tsubota A; Hashimoto M; Miyano Y; Koike H; Kobayashi M; Koida I; Arase Y; Saitoh S; Murashima N; Ikeda K; Kumada H
Hepatology; 1998 Jun; 27(6):1711-6. PubMed ID: 9620347
[TBL] [Abstract][Full Text] [Related]
3. Emergence of YMDD motif mutants of hepatitis B virus during lamivudine treatment of immunocompetent type B hepatitis patients.
Seta T; Yokosuka O; Imazeki F; Tagawa M; Saisho H
J Med Virol; 2000 Jan; 60(1):8-16. PubMed ID: 10568756
[TBL] [Abstract][Full Text] [Related]
4. Emergence of YMDD motif mutant of hepatitis B virus during short-term lamivudine therapy in South Korea.
Paik YH; Chung HY; Ryu WS; Lee KS; Lee JS; Kim JH; Lee CK; Chon CY; Moon YM; Han KH
J Hepatol; 2001 Jul; 35(1):92-8. PubMed ID: 11495048
[TBL] [Abstract][Full Text] [Related]
5. Detection of YMDD motif mutants by oligonucleotide chips in lamivudine-untreated patients with chronic hepatitis B virus infection.
Heo J; Cho M; Kim HH; Shin YM; Jang HJ; Park HK; Kim CM; Kim GH; Kang DH; Song GA; Yang US
J Korean Med Sci; 2004 Aug; 19(4):541-6. PubMed ID: 15308845
[TBL] [Abstract][Full Text] [Related]
6. YMDD mutants in patients with chronic hepatitis B before treatment are not selected by lamivudine.
Matsuda M; Suzuki F; Suzuki Y; Tsubota A; Akuta N; Hosaka T; Someya T; Kobayashi M; Saitoh S; Arase Y; Satoh J; Kobayashi M; Ikeda K; Miyakawa Y; Kumada H
J Med Virol; 2004 Oct; 74(2):361-6. PubMed ID: 15332287
[TBL] [Abstract][Full Text] [Related]
7. Early detection of viral resistance by determination of hepatitis B virus polymerase mutations in patients treated by lamivudine for chronic hepatitis B.
Nafa S; Ahmed S; Tavan D; Pichoud C; Berby F; Stuyver L; Johnson M; Merle P; Abidi H; Trépo C; Zoulim F
Hepatology; 2000 Nov; 32(5):1078-88. PubMed ID: 11050059
[TBL] [Abstract][Full Text] [Related]
8. [Natural YMDD motif mutations of HBV polymerase in the chronic hepatitis B virus infected patients].
Shin YM; Heo J; Kim GH; Kang DH; Song GA; Cho M; Yang US; Kim CM; Park HK; Jang HJ
Taehan Kan Hakhoe Chi; 2003 Mar; 9(1):1-9. PubMed ID: 12657823
[TBL] [Abstract][Full Text] [Related]
9. Genotypic and phenotypic resistance: longitudinal and sequential analysis of hepatitis B virus polymerase mutations in patients with lamivudine resistance after liver transplantation.
Ben-Ari Z; Daudi N; Klein A; Sulkes J; Papo O; Mor E; Samra Z; Gadba R; Shouval D; Tur-Kaspa R
Am J Gastroenterol; 2003 Jan; 98(1):151-9. PubMed ID: 12526951
[TBL] [Abstract][Full Text] [Related]
10. Hepatitis B virus (HBV) genotype and YMDD motif mutation profile among patients infected with HBV and untreated with lamivudine.
Amini-Bavil-Olyaee S; Hosseini SY; Sabahi F; Alavian SM
Int J Infect Dis; 2008 Jan; 12(1):83-7. PubMed ID: 17698384
[TBL] [Abstract][Full Text] [Related]
11. [Types and emergence time of YMDD motif mutation in hepatitis B virus polymerase gene during lamivudine treatment].
Liang WF; Yang DH; Shen YH; Xie YJ; Zhao NF
Zhonghua Gan Zang Bing Za Zhi; 2003 May; 11(5):302-4. PubMed ID: 12773248
[TBL] [Abstract][Full Text] [Related]
12. Acute exacerbation and hepatitis B virus clearance after emergence of YMDD motif mutation during lamivudine therapy.
Liaw YF; Chien RN; Yeh CT; Tsai SL; Chu CM
Hepatology; 1999 Aug; 30(2):567-72. PubMed ID: 10421670
[TBL] [Abstract][Full Text] [Related]
13. [YMDD motif variants detected by Inno-Lipa HBV DR assay in chronic hepatitis B patients during lamivudine therapy].
Arslan U; Ural O; Findik D
Mikrobiyol Bul; 2008 Jul; 42(3):445-50. PubMed ID: 18822888
[TBL] [Abstract][Full Text] [Related]
14. Rapid detection of lamivudine-resistant hepatitis B virus polymerase gene variants.
Jardi R; Buti M; Rodriguez-Frias F; Cotrina M; Costa X; Pascual C; Esteban R; Guardia J
J Virol Methods; 1999 Dec; 83(1-2):181-7. PubMed ID: 10598095
[TBL] [Abstract][Full Text] [Related]
15. Clinical and virological features of non-breakthrough and severe exacerbation due to lamivudine-resistant hepatitis B virus mutants.
Suzuki F; Akuta N; Suzuki Y; Sezaki H; Arase Y; Hosaka T; Someya T; Kobayashi M; Saitoh S; Ikeda K; Kobayashi M; Matsuda M; Satoh J; Watahiki S; Kumada H
J Med Virol; 2006 Mar; 78(3):341-52. PubMed ID: 16419116
[TBL] [Abstract][Full Text] [Related]
16. Association of core promoter mutations with viral breakthrough in chronic hepatitis B patients on long-term lamivudine therapy.
Kazim SN; Chauhan R; Das BC; Sarin SK
J Gastroenterol Hepatol; 2006 Oct; 21(10):1525-32. PubMed ID: 16928212
[TBL] [Abstract][Full Text] [Related]
17. Factors associated with viral breakthrough in lamivudine monoprophylaxis of hepatitis B virus recurrence after liver transplantation.
Chan HL; Chui AK; Lau WY; Chan FK; Wong ML; Tse CH; Rao AR; Wong J; Sung JJ
J Med Virol; 2002 Oct; 68(2):182-7. PubMed ID: 12210406
[TBL] [Abstract][Full Text] [Related]
18. Genotypic succession of mutations of the hepatitis B virus polymerase associated with lamivudine resistance.
Gutfreund KS; Williams M; George R; Bain VG; Ma MM; Yoshida EM; Villeneuve JP; Fischer KP; Tyrrel DL
J Hepatol; 2000 Sep; 33(3):469-75. PubMed ID: 11020004
[TBL] [Abstract][Full Text] [Related]
19. Selection of hepatitis B virus polymerase mutants with enhanced replication by lamivudine treatment after liver transplantation.
Bock CT; Tillmann HL; Torresi J; Klempnauer J; Locarnini S; Manns MP; Trautwein C
Gastroenterology; 2002 Feb; 122(2):264-73. PubMed ID: 11832441
[TBL] [Abstract][Full Text] [Related]
20. Factors associated with hepatitis B virus DNA breakthrough in patients receiving prolonged lamivudine therapy.
Yuen MF; Sablon E; Hui CK; Yuan HJ; Decraemer H; Lai CL
Hepatology; 2001 Oct; 34(4 Pt 1):785-91. PubMed ID: 11584376
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
